Global Lipid Nanoparticles (LNPs) CDMO Market, by Product,
Global Lipid Nanoparticles (LNPs) CDMO Market, by Scale of Operation,
Global Lipid Nanoparticles (LNPs) CDMO Market, by By End-Users,
Global Lipid Nanoparticles (LNPs) CDMO Market, by Region,
North America Lipid Nanoparticles (LNPs) CDMO Market, by Country,
Europe Lipid Nanoparticles (LNPs) CDMO Market, by Country,
Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market, by Country,
Latin America Lipid Nanoparticles (LNPs) CDMO Market, by Country,
Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market, by Country,
Competitive Landscape
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs) Snapshot
Chapter 4. Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs) Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis: Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
4.9. Clinical Trial/Pipeline Analysis
4.10. Application of mRNA Beyond COVID 19 Vaccine
Chapter 5. Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. By Products, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. mRNA
5.2.2. Plasmid DNA (pDNA)
5.2.3. siRNA
5.2.4. saRNA
5.2.5. microRNA
5.2.6. Other Products
Chapter 6. Market Segmentation 2: By End-Users Estimates & Trend Analysis
6.1. By End-Users & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-Users:
6.2.1. Pharmaceutical Companies
6.2.2. Academic Research Institute
6.2.3. Diagnostic Laboratory
Chapter 7. Market Segmentation 3: By Scale of Operation Estimates & Trend Analysis
7.1. By Scale of Operation & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Scale of Operation:
7.2.1. Preclinical
7.2.2. Clinical
7.2.3. Commercial
Chapter 8. Lipid Nanoparticles (LNPs) CDMO Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
8.1.2. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By End-Users, 2021-2034
8.1.3. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2021-2034
8.1.4. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, 2021-2034
8.2.2. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, 2021-2034
8.2.3. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, 2021-2034
8.2.4. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, 2021-2034
8.3.2. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, 2021-2034
8.3.3. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, 2021-2034
8.3.4. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.4.2. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, (US$ Million) 2021-2034
8.4.3. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
8.4.4. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
8.5.2. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, (US$ Million) 2021-2034
8.5.3. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
8.5.4. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Corden Pharma GmbH
9.2.2. eTheRNA
9.2.3. Curapath (Polypeptide Therapeutic Solutions (PTS))
9.2.4. FUJIFILM Corporation
9.2.5. ST Pharm Co Ltd
9.2.6. Exelead (Merck KGaA)
9.2.7. Avanti Polar Lipids, Inc. (Croda International Plc.)
9.2.8. Emergent CDMO
9.2.9. Esco Aster Pte Ltd
9.2.10.Vernal Biosciences
9.2.11.Recipharm AB
9.2.12.Ardena Holding NV
9.2.13.Curia Global, Inc.
9.2.14.Helix Biotech
9.2.15.Phosphorex Inc
9.2.16.Polymun Scientific Immunbiologische Forschung GmbH
9.2.17.Lonza Group AG
9.2.18.Evonik
9.2.19.Samsung Biologics
9.2.20.Catalent, Inc
9.2.21.Genevant Sciences
9.2.22. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.